Safety Monitoring of Medicinal Products: Guidelines for Setting Up and Running a Pharmacovigilance Centre
(2000; 28 pages) [French]
Table des matières
Afficher le documentINTRODUCTION
Afficher le document1. WHY PHARMACOVIGILANCE?
Afficher le document2. DEFINITION AND AIMS
Ouvrir ce répertoire et afficher son contenu3. HOW TO START A PHARMACOVIGILANCE CENTRE
Ouvrir ce répertoire et afficher son contenu4. REPORTING OF ADVERSE DRUG REACTIONS
Ouvrir ce répertoire et afficher son contenu5. SPECIAL ISSUES IN REPORTING
Ouvrir ce répertoire et afficher son contenu6. PRACTICALITIES IN THE ORGANISATION OF A PHARMACOVIGILANCE CENTRE
Ouvrir ce répertoire et afficher son contenu7. ASSESSMENT OF CASE REPORTS
Ouvrir ce répertoire et afficher son contenu8. USE OF THE DATA
Ouvrir ce répertoire et afficher son contenu9. RELATIONS WITH OTHER PARTIES
Afficher le document10. OTHER SOURCES OF INFORMATION
Afficher le document11. FUNDING
Afficher le documentREFERENCES
Afficher le documentGLOSSARY
Afficher le documentCAUSALITY CATEGORIES
Afficher le documentWHO CONTACTS
 

10. OTHER SOURCES OF INFORMATION

Spontaneous Reporting is especially useful in picking up signals of relatively rare, serious and unexpected adverse reactions. For less rare adverse reactions several other methods may be used, e.g. clinical trials or cohort studies. In addition to spontaneous reporting several other methods have become available to provide data relevant to pharmacovigilance. Examples are: Prescription Event Monitoring, Case-Control Surveillance and linkage of records from multipurpose databases. In addition, drug utilisation data is of value in safety assessment.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013